

proposes to issue a concession permit to Frank P. Dickinson (Swan Tavern Antiques) authorizing him to provide concession facilities and services for the public at Colonial National Historical Park for a period of three (3) years from January 1, 1973, through December 31, 1975.

The foregoing concessioner has performed its obligations under a prior permit to the satisfaction of the National Park Service and, therefore, pursuant to the Act cited above, is entitled to be given preference in the renewal of the permit and in the negotiation of a new permit. However, under the Act cited above, the Secretary is also required to consider and evaluate all proposals received as a result of this notice. Any proposal to be considered and evaluated must be submitted within thirty (30) days after the publication date of this notice.

Interested parties should contact the Chief of Concessions Management, National Park Service, Washington, D.C. 20240, for information as to the requirements of the proposed permit.

Dated: February 1, 1973.

LAWRENCE C. HADLEY,
Assistant Director,
National Park Service.

[FR Doc.73-2680 Filed 2-8-73;8:45 am]


DEPARTMENT OF AGRICULTURE

Office of the Secretary

SAWTOOTH NATIONAL RECREATION AREA Area Description

Correction

In FR Doc. 73-1685 appearing at page 2992 in the issue for Wednesday, January 31, 1973, the following map should be included at the end of the text:



Soil Conservation Service BUFFALO RIVER WATERSHED PROJECT, VA.

Notice of Availability of Draft Environmental Statement

Pursuant to section 102(2)(C) of the National Environmental Policy Act of 1969, the U.S. Department of Agriculture, Soil Conservation Service, has prepared a draft environmental statement for the Buffalo River Watershed Project, Amherst County, Va., USDA-SCS-ES-WS-(ADM)-73-27(D).

The environmental statement concerns a plan for watershed protection, flood prevention, and municipal and industrial water supply. The planned works of improvement include conservation land treatment measures, two single-purpose floodwater retarding structures, and two multiple-purpose structures for storage of floodwater and sediment and municipal water supply.

This draft environmental statement was transmitted to CEQ on February 5, 1973.

Copies are available during regular working hours at the following locations:

Soil Conservation Service, USDA, South Agriculture Building, Room 5227, 12th and Independence Avenue SW., Washington, DC 20250.

Soil Conservation Service, USDA, Federal Building, Room 7408, 400 North Eighth Street, Post Office Box 10026, Richmond, VA 23240.

Copies are also available from the National Technical Information Service, U.S. Department of Commerce, Springfield, Va. 22151. Please refer to the name and number of statement above when ordering. The estimated cost is \$3.25.

Copies of the draft environmental statement have been sent for comment to various Federal, State, and local agencies as outlined in the Council on Environmental Quality Guidelines. Comments are invited from anyone having knowledge of or special expertise with respect to environmental impacts.

Comments concerning the proposed action and requests for additional information should be addressed to Mr. D. N. Grimwood, Federal Building, Room 7408, 400 North Eighth Street, Post Office Box 10026, Richmond, VA 23240.

Comments must be received on or before April 6, 1973, in order to be considered in the preparation of the final environmental statement.

EUGENE C. BUIE,
Acting Deputy Administrator
for Watersheds, Soil Conservation Service.

FEBRUARY 6, 1973.

[FR Doc.73-2744 Filed 2-9-73;8:45 am]

**KIOKEE CREEK WATERSHED PROJECT,
GEORGIA**
**Notice of Availability of Draft
Environmental Statement**

Pursuant to section 102(2)(C) of the National Environmental Policy Act of 1969, the Soil Conservation Service, U.S. Department of Agriculture, has prepared a draft environmental statement for the Kiokee Creek Watershed Project, Columbia and McDuffie Counties, Ga., USDA-SCS-ES-WS-(ADM)-73-2-(D).

The environmental statement concerns a plan for watershed protection, flood prevention, recreation, fish and wildlife improvement, irrigation, and industrial water supply. The planned works of improvement include conservation land treatment throughout the watershed, supplemented by (1) two single-purpose floodwater retarding structures, (2) one multiple-purpose structure for flood prevention and public recreation and associated recreation facilities, (3) one multiple-purpose structure for flood prevention and industrial water supply, (4) one multiple-purpose structure for flood prevention and irrigation water supply, (5) 5.9 miles of channel modification for flood prevention, (6) a fish and wildlife improvement area for public recreation, and (7) 120 acres of critical area treatment.

This draft environmental statement was transmitted to CEQ on February 6, 1973.

Copies are available during regular working hours at the following locations:

Soil Conservation Service, USDA, South Agriculture Building, Room 5227, 14th and Independence Avenue SW, Washington, DC 20250.

Soil Conservation Service, USDA, Heritage Building, 468 North Millidge Avenue, Athens, GA 30601.

Copies are also available from the National Technical Information Service, U.S. Department of Commerce, Springfield, Va. 22151. Please use name and number of statement above when ordering. The estimated cost is \$3.50.

Copies of the draft environmental statement have been sent for comment to various Federal, State, and local agencies as outlined in the Council on Environmental Quality Guidelines. Comments are also invited from others having knowledge of or special expertise on environmental impacts.

Comments concerning the proposed action or requests for additional information should be addressed to Charles W. Bartlett, State Conservationist, Soil Conservation Service, Post Office Box 832, Athens, GA 30601.

Comments must be received on or before April 9, 1973, in order to be considered in the preparation of the final environmental statement.

EUGENE C. BUIE,
*Acting Deputy Administrator
for Watersheds, Soil Conservation Service.*

FEBRUARY 6, 1973.

[FR Doc.73-2745 Filed 2-9-73; 8:45 am]

POINSETT WATERSHED PROJECT, ARK.
**Notice of Availability of Draft
Environmental Statement**

Pursuant to section 102(2)(C) of the National Environmental Policy Act of 1969, the Soil Conservation Service, U.S. Department of Agriculture, has prepared a draft environmental statement for the Poinsett Watershed Project, Poinsett and Craighead Counties, Ark., USDA-SCS-ES-WS-(ADM)-73-2-(D).

The environmental statement concerns a plan for watershed protection, flood prevention, and treatment of critical erosion areas. The planned works of improvement include conservation land treatment, 47 floodwater retarding structures, 22 miles of resectioning a man-made ditch, and treatment of 638 acres of critical erosion areas.

This draft environmental statement was transmitted to CEQ on January 22, 1973.

Copies are available during regular working hours at the following locations:

Soil Conservation Service, USDA, South Agriculture Building, Room 5227, 14th and Independence Avenue SW, Washington, DC 20250.

Soil Conservation Service, USDA, Post Office Box 2323, Little Rock, AR 72203.

Copies are also available from the National Technical Information Service, U.S. Department of Commerce, Springfield, Va. 22151. Please use name and number of statement above when ordering. The estimated cost is \$4.

Copies of the draft environmental statement have been sent for comment to various Federal, State, and local agencies as outlined in the Council on Environmental Quality Guidelines. Comments are also invited from others having knowledge of or special expertise on environmental impacts.

Comments concerning the proposed action or requests for additional information should be addressed to Einar L. Roget, State Conservationist, Soil Conservation Service, Post Office Box 2323, Little Rock, AR 72203.

Comments must be received on or before March 23, 1973, in order to be considered in the preparation of the final environmental statement.

EUGENE C. BUIE,
*Acting Deputy Administrator
for Watersheds, Soil Conservation Service.*

FEBRUARY 6, 1973.

[FR Doc.73-2746 Filed 2-9-73; 8:45 am]

DEPARTMENT OF COMMERCE
Office of the Secretary

[Dept. Org. Order 10-3, Amdt. 1]

**ASSISTANT SECRETARY FOR DOMESTIC
AND INTERNATIONAL BUSINESS**
Organization and Functions

This order effective January 27, 1973, amends the material appearing at 37 FR 25555 of December 1, 1972.

Department Organization Order 10-3, dated November 17, 1972, is hereby amended as follows:

2. In Section 3. *Scope of authority*, subparagraphs .03b. through .03f. are revised to read:

b. The Deputy Assistant Secretary for Competitive Assessment and Business Policy.

c. The Deputy Assistant Secretary for International Commerce who shall also be the National Export Expansion Coordinator.

d. The Deputy Assistant Secretary for Resources and Trade Assistance.

e. The Deputy Assistant Secretary for East-West Trade.

f. The Deputy Assistant Secretary for Administrative Management, DIBA.

3. In Section 5. *Delegation of authority*, a. Subparagraphs .01b., .01d., .01p., and .01q. are revised to read:

b. The Defense Production Act of 1950, as amended (50 U.S.C. App. 2061 et seq.), conferred on the Secretary under Executive Order 10480, dated August 14, 1953, as amended, including authority to issue or modify orders restricting surface transportation and discharge of certain commodities or for the prohibition of movement of American carriers to certain designated destinations, which authority has heretofore been implemented by the issuance of Transportation Orders T-1 and T-2, except the authority to create new agencies within the Department of Commerce;

d. Executive Order 11490 of October 28, 1969, as it relates to the development of national emergency preparedness plans and programs concerning production functions and to the regulation and control of exports and imports under the jurisdiction of the Department, in support of national security, foreign policy, and economic stabilization objectives;

p. Headnote 6 (d) of Schedule 7, part 2, subpart E of the Tariff Schedules of the United States (19 U.S.C. 1202), added by Public Law 89-805, pertaining to the allocation of quotas for duty-free importation into the customs territory of the United States of watches and watch movements, among producers located in the Virgin Islands, Guam, and American Samoa, respectively;

q. The Trade Expansion Act of 1962 (19 U.S.C. 1801 et seq.) and Executive Order 11075 of January 15, 1963, as amended by Executive Order 11106 of April 18, 1963;

b. In the last line of subparagraph .01v., delete the word "and."

c. Add the following new subparagraphs .01x. and .01y.:

x. The Act of October 27, 1972 (P.L. 92-598; 84 Stat. 271) relating to the participation of the United States in the International Exposition on the Environment to be held in Spokane, Washington, in 1974; and

y. The Acts of February 19, 1966 (P.L. 89-355) and October 27, 1966 (P.L. 89-697) regarding the participation of the

United States in the Inter-American Cultural and Trade Center in Dade County, Fla. (Interama).

Effective date: January 27, 1973.

GUY W. CHAMBERLIN, Jr.,
Acting Assistant Secretary
for Administration.

[FR Doc. 73-2654 Filed 2-9-73; 8:45 am]

Social and Economic Statistics Administration

NUMBER OF EMPLOYEES, TAXABLE WAGES, GEOGRAPHIC LOCATION AND KIND OF BUSINESS FOR ESTABLISHMENTS OF MULTIUNIT COMPANIES

Notice of Consideration for Surveys

Notice is hereby given that the Bureau of the Census is considering a proposal under the provisions of title 13, United States Code, sections 181, 224, and 225, to conduct a First Quarter 1973 Survey of Selected Multiunit Companies. This survey is similar to those conducted for previous County Business Patterns Reports. It is designed to collect information for the 1973 report on the number of employees, taxable wages, geographic location, and kind of business for the establishments of certain multi-unit companies. The data will have significant application to the needs of the public and to governmental agencies and are not publicly available from nongovernmental or governmental sources.

The survey, if conducted, shall begin not earlier than 30 days after publication of this notice in the FEDERAL REGISTER.

Copies of the proposed form are available on request to the Director, Bureau of the Census, Washington, D.C. 20233.

Any suggestions or recommendations concerning the subject matter of the proposed survey submitted to the Director in writing on or before March 14, 1973, will receive consideration.

Dated: February 6, 1973.

JOSEPH R. WRIGHT, Jr.,
Acting Administrator, Social
and Economic Statistics Administration.

[FR Doc. 73-2695 Filed 2-9-73; 8:45 am]

DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE

Food and Drug Administration

[DESI 5378; Docket No. FDC-D-582; NDA No. 9-946 etc.]

CERTAIN COMBINATION ANORECTIC DRUGS

Opportunity for Hearing on Proposal to Withdraw Approval of New Drug Applications

In a notice (DESI 5378) published in the FEDERAL REGISTER of August 8, 1970 (35 FR 12678), the Commissioner of Food and Drugs announced his conclusions pursuant to the evaluation of a report received from the National Academy of Sciences-National Research

Council, Drug Efficacy Study Group, on the drugs described below stating that the drugs were regarded as possibly

effective and lacking substantial evidence of effectiveness for the various labeled indications.

NDA No.	Drug	NDA Holder
9-946	Du-Orla tablets containing 10 milligrams methamphetamine hydrochloride, and 0.25 milligram reserpine per sustained release tablet.	Formerly marketed by B. F. Ascher & Co., Inc., Post Office Box 827, Kansas City, MO 64130.
19-207	Desserpine "5" tablets containing 5 milligrams dextroamphetamine sulfate and 0.1 milligram reserpine per tablet.	Formerly marketed by Nyco Laboratories, Inc., 34-24 Vernon Boulevard, Long Island City, N.Y. 11106.
11-280	Bamadex tablets containing 5 milligrams dextroamphetamine sulfate and 400 milligrams meprobamate per tablet.	Lederle Laboratories Division, American Cyanamid Co., Post Office Box 990, Pearl River, N.Y. 10965.
11-522	Obetrol-10 and Obetrol-20 tablets, respectively, containing 2.5 milligrams each or 5 milligrams each of methamphetamine mesochate, methamphetamine hydrochloride, amphetamine sulfate, dextroamphetamine sulfate per tablet.	Obetrol Pharmaceuticals, Division of Rexar Pharmaceutical Corp., 382 Schenck Avenue, Brooklyn, N.Y. 11207.
11-538	Biphetamine-T "12 1/2" capsules and Biphetamine-T "20" capsules, respectively, containing 6.25 milligrams each of dextroamphetamine and amphetamine, and 40 milligrams methaqualone per capsule, and 10 milligrams each of dextroamphetamine and amphetamine and 40 milligrams methaqualone per capsule, all as cation exchange resin complexes of sulfonated polystyrene.	Strassenburgh Pharmaceutical, Division Pennwalt Corp., 755 Jefferson Road, Rochester NY 14623.
12-042	Eskatrol Tablets containing 15 milligrams dextroamphetamine sulfate and 7.5 milligrams prochlorperazine (as the maleate) per sustained release capsule.	Smith Kline & French Laboratories, 1500 Spring Garden Street, Philadelphia, PA 19101.
12-127	Appetrol tablets containing 5 milligrams dextroamphetamine sulfate and 400 milligrams meprobamate per tablet.	Wallace Pharmaceuticals, Division of Carter-Wallace, Inc., Half Aero Road, Cranbury, NJ 08512.
12-371	Preh-Vite capsules containing 25 milligrams phenmetrazine hydrochloride, 2,000 USP units vitamin A, 200 USP units vitamin D, 2 milligrams thiamine mononitrate, 2 milligrams riboflavin, 20 milligrams niacinamide, 3 milligrams calcium pantothenate, 1 milligram pyridoxine hydrochloride, 0.5 microgram cobalamin concentrate, 37.5 milligrams ascorbic acid, 5 milligrams iron, 140 milligrams calcium, 108 milligrams phosphorus, 0.1 milligram iodine and 1 milligram copper per capsule.	Formerly marketed by Geigy Pharmaceuticals, Division of Ciba Geigy Co., Saw Mill River Road, Ardsley, N.Y. 10502.
12-415	Delta-6 Sed Tablets containing 30 milligrams di-methamphetamine hydrochloride and 120 milligrams amobarbital per sustained-release tablet.	Eastern Research Laboratories Inc., 302 South Central Avenue, Baltimore, MD 21202.
12-570	Bamadex Sequels containing 15 milligrams dextroamphetamine sulfate and 300 milligrams meprobamate per sustained-release capsule.	Lederle Laboratories Division, American Cyanamid.
12-624	Appetrol-S.R. capsules containing 15 milligrams dextroamphetamine sulfate and 300 milligrams meprobamate per sustained-release capsule.	Wallace Pharmaceuticals.

Data submitted pursuant to the notice have been reviewed and found not to provide substantial evidence that the drugs are effective as fixed combinations for their claimed uses.

In view of the lack of substantial evidence of effectiveness of the drugs as fixed combinations, the recognized potential for abuse of the amphetamine, dextroamphetamine, methamphetamine, and phenmetrazine components, and the availability of alternative therapeutic measures which are safer and effective, the combination products are also regarded as lacking proof of safety. Data submitted in response to the notice of August 8, 1970, do not support a contention that the combination products decrease the incidence or severity of side effects associated with the single ingredient or that the additional component(s) lessens the abuse potential as compared to that of the single entity anorectic drug. Also, the known adverse effects associated with phenothiazine drugs raises an additional question of safety of use of Eskatrol which contains dextroamphetamine sulfate in combination with prochlorperazine.

With further respect to Eskatrol, the Food and Drug Administration is aware of a study conducted by Dr. Carl Chambers relating to the abuse potential of the product, and for which no report has been submitted by the NDA holder pursuant to section 505(j) of the act and §§ 130.13 and 130.35 of the regulations (21 CFR 130.13 and 130.35).

Therefore, notice is given to the holder(s) of the new drug application(s)

and to any other interested person that the Commissioner proposes to issue an order under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) withdrawing approval of the listed new drug application(s) and all amendments and supplements thereto on the grounds that new information before him with respect to the drug(s), evaluated together with the evidence available to him at the time of approval of the application(s), shows that: (1) There is a lack of substantial evidence that the drug(s) will have all the effects they purport or are represented to have; and (2) the drugs are not shown to be safe for use under the conditions of use prescribed, recommended, or suggested in the labeling; and (3) further, in the case of Eskatrol tablets, the applicant has deliberately failed to make required reports in accordance with section 505(j) of the act (21 U.S.C. 355(j)) and § 130.13 and § 130.35 of the new drug regulations (21 CFR 130.13 and 130.35).

All identical, related, or similar products, not the subject of an approved new drug application, are covered by the new drug application(s) reviewed. See 21 CFR 130.40 (37 FR 23185, October 31, 1972). Any manufacturer or distributor of such an identical, related, or similar product is an interested person who may in response to this notice submit data and information, request that the new drug application(s) not be withdrawn, request a hearing, and participate as a party in any hearing. Any person who wishes to determine whether a specific product is covered by this notice should write to the

Food and Drug Administration, Bureau of Drugs, Office of Compliance (BD-300), 5600 Fishers Lane, Rockville, MD 20852.

In accordance with the provisions of section 505 of the act (21 U.S.C. 355) and the regulations promulgated thereunder (21 CFR Part 130), the Commissioner hereby gives the applicant(s) and any other interested person an opportunity to a hearing to show why approval of the new drug application(s) should not be withdrawn.

The applicant(s) and any other interested person is required to file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-88, 5600 Fishers Lane, Rockville, MD 20852, on or before March 14, 1973, a written appearance electing whether or not to avail himself of the opportunity for a hearing. Failure of an applicant or any other interested person to file a written appearance of election by March 14, 1973, will constitute an election by him not to avail himself of the opportunity for a hearing.

If no person elects to avail himself of the opportunity for a hearing, the Commissioner without further notice will enter a final order withdrawing approval of the application(s).

If an applicant or any other interested person elects to avail himself of the opportunity for a hearing, he must file, on or before March 14, 1973, a written appearance requesting the hearing, giving the reasons why approval of the new drug application(s) should not be withdrawn, together with a well-organized and full-factual analysis of the clinical and other investigational data he is prepared to prove in support of his opposition. A request for a hearing may not rest upon mere allegations or denials, but must set forth specific facts showing that a genuine and substantial issue of fact requires a hearing (21 CFR 130.14(b)).

If review of the data submitted by an applicant or any other interested person warrants the conclusion that there exists substantial evidence demonstrating the effectiveness of the product(s) and evidence that the drug(s) is (are) safe for use for the labeling claims involved (and, in the case of NDA 12-042, that there has been no violation of section 505(j) of the act), the Commissioner will rescind this notice of opportunity for hearing.

If review of the data in the application(s) and data submitted by the applicant(s) or any other interested person in a request for a hearing, together with the reasoning and factual analysis in a request for a hearing, warrants the conclusion that no genuine and substantial issue of fact precludes the withdrawal of approval of the application(s), the Commissioner will enter an order of withdrawal making findings and conclusions on such data.

If, upon the request of the new drug applicant(s) or any other interested person, a hearing is justified, the issues will be defined, a hearing examiner will be named, and he shall issue, as soon as practicable after March 14, 1973, a written notice of the time and place at which the hearing will commence. All persons

interested in identical, related, or similar products covered by the new drug application(s) will be afforded an opportunity to appear at the hearing, file briefs, present evidence, cross-examine witnesses, submit suggested findings of fact, and otherwise participate as a party. The hearing contemplated by this notice will be open to the public except that any portion of the hearing that concerns a method or process the Commissioner finds entitled to protection as a trade secret will not be open to the public, unless the respondent specifies otherwise in his appearance.

Requests for a hearing and/or elections not to request a hearing may be seen in the Office of the Hearing Clerk (address given above) during regular business hours, Monday through Friday.

This notice is issued pursuant to provisions of the Federal Food, Drug, and Cosmetic Act (sec. 505, 52 Stat. 1052-53, as amended; 21 U.S.C. 355), and the Administrative Procedure Act (5 U.S.C. 554), and under authority delegated to the Commissioner (21 CFR 2.120).

Dated: February 7, 1973.

WILLIAM F. RANDOLPH,
Acting Associate Commissioner
for Compliance.

[FR Doc.73-2716 Filed 2-9-73; 8:45 am]

[DESI 11673]

CERTAIN ORAL ANORECTIC PREPARATIONS: PHENTERMINE HYDROCHLORIDE; PHENDIMETRAZINE TARTRATE; BENZPHETAMINE HYDROCHLORIDE; DIETHYLPROPION HYDROCHLORIDE

Drugs for Human Use; Drug Efficacy Study Implementation

The Food and Drug Administration has evaluated reports received from the National Academy of Sciences-National Research Council, Drug Efficacy Study Group, on the following anorectic drugs:

1. Wilpo tablets, containing 8 mg. phentermine hydrochloride per tablet; Dorsey Laboratories, Division of Sandoz-Wander Inc., Northeast, U.S. 6 and Interstate 80, Lincoln, Nebr. 68501 (NDA 12-737).
2. Didrex tablets, containing 25 mg. and 50 mg. benzphetamine hydrochloride per tablet; The Upjohn Co., 7171 Portage Road, Kalamazoo, MI 49001 (NDA 12-427).
3. Plegine tablets, containing 35 mg. phendimetrazine tartrate per tablet; Ayerst Laboratories, Rouses Point, N.Y. 13979 (NDA 12-248).
4. Tepanil tablets, containing 25 mg. diethylpropion hydrochloride per tablet; The Merrell-National Drug Co., Division of Richardson-Merrell, Inc., 110 East Amity Road, Cincinnati, OH 45215 (NDA 11-673).
5. Tenuate tablets, containing 25 mg. diethylpropion hydrochloride per tablet; The Merrell-National Drug Co., Division of Richardson-Merrell, Inc. (NDA 11-722).
6. Preludin Endurets (prolonged-action tablets), containing phenmetra-

zine hydrochloride; Geigy Pharmaceuticals, Division of Ciba-Geigy Corp., Ardley, N.Y. 10502 (NDA 11-752).

Although not specifically referred to the Academy for review, Preludin tablets, a conventional oral dosage form containing phenmetrazine hydrochloride (NDA 10-460, Geigy Pharmaceuticals) was approved on the basis of safety prior to 1962, was evaluated by the Academy, and is appropriately included herein.

Such drugs are regarded as new drugs (21 U.S.C. 321(p)). Supplemental new drug applications are required to revise the labeling in and to update previously approved applications providing for such drugs. A new drug application is required from any person marketing such drug without approval.

I. SUSTAINED-ACTION, TIMED-RELEASE, OR OTHER DELAYED OR PROLONGED-EFFECT FORMS OF PHENMETRAZINE HYDROCHLORIDE

The Food and Drug Administration has considered the Academy's report, as well as other available evidence, and concludes that phenmetrazine hydrochloride in prolonged-action tablet form is less than effective (possibly effective) with respect to any special claim for prolonged action when offered for the management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction.

Any data submitted in response to this notice to support claims for which the drug is classified as other than effective must be previously unsubmitted and include data from adequate and well-controlled clinical investigations (identified for ready review) as described in § 130.12 (a) (5) of the regulations published in the FEDERAL REGISTER of May 8, 1970 (35 FR 7250). Carefully conducted and documented clinical studies obtained under uncontrolled or partially controlled situations are not acceptable as a sole basis for approval of claims of effectiveness, but such studies may be considered on their merits for corroborative support of efficacy and evidence of safety.

II. CONVENTIONAL TABLET FORMS OF PHENMETRAZINE HYDROCHLORIDE; PHENTERMINE HYDROCHLORIDE; BENZPHETAMINE HYDROCHLORIDE; PHENDIMETRAZINE TARTRATE; OR DIETHYLPROPION HYDROCHLORIDE

A. Effectiveness classification. The Food and Drug Administration has considered the Academy's reports, as well as other available evidence, and concludes that these drugs, administered in conventional oral dosage form, are effective in the management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction.

B. Conditions for approval and marketing. The Food and Drug Administration is prepared to approve abbreviated new drug applications and abbreviated supplements to previously approved new drug applications under conditions described herein.

1. *Form of drug.* Such preparations are in tablet dosage form suitable for oral administration.

2. *Labeling conditions.* The label bears the statement, "Caution: Federal law prohibits dispensing without prescription."

The drugs are labeled to comply with all requirements of the Act and regulations, and the labeling bears adequate information for safe and effective use of the drug(s). The "Indications" section is as follows:

INDICATIONS

(Name of drug) is indicated in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction. The limited usefulness of agents of this class (see ACTIONS) should be measured against possible risk factors inherent in their use such as those described below.

In addition, the labeling contains the following "Actions" section and drug dependence warning the "Warnings" section:

ACTIONS

(Name of drug) is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.

Drugs of this class used in obesity are commonly known as "anorectics" or "anorexigenics". It has not been established, however, that the action of such drugs in treating obesity is primarily one of appetite suppression. Other central nervous system actions, or metabolic effects, may be involved, for example.

Adult obese subjects instructed in dietary management and treated with "anorectic" drugs, lose more weight on the average than those treated with placebo and diet, as determined in relatively short-term clinical trials.

The magnitude of increased weight loss of drug-treated patients over placebo-treated patients is only a fraction of a pound a week. The rate of weight loss is greatest in the first weeks of therapy for both drug and placebo subjects and tends to decrease in succeeding weeks. The possible origins of the increased weight loss due to the various drug effects are not established. The amount of weight loss associated with the use of an "anorectic" drug varies from trial to trial, and the increased weight loss appears to be related in part to variables other than the drug prescribed, such as the physician-investigator, the population treated, and the diet prescribed. Studies do not permit conclusions as to the relative importance of the drug and non-drug factors on weight loss.

The natural history of obesity is measured in years, whereas the studies cited are restricted to a few weeks duration; thus, the total impact of drug-induced weight loss over that of diet alone must be considered clinically limited.

WARNINGS

DRUG DEPENDENCE: (Name of drug) is related chemically and pharmacologically to the amphetamines. Amphetamines and related stimulant drugs have been extensively abused, and the possibility of abuse of (name of drug) should be kept in mind when evaluating the desirability of including a drug as part of a weight reduction program. Abuse of amphetamines and related drugs may be

associated with intense psychological dependence and severe social dysfunction. There are reports of patients who have increased the dosage to many times that recommended. Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG. Manifestations of chronic intoxication with anorectic drugs include severe dermatoses, marked insomnia, irritability, hyperactivity, and personality changes. The most severe manifestation of chronic intoxications is psychosis, often clinically indistinguishable from schizophrenia.

3. *Marketing status.* Marketing of such drugs may be continued under the conditions described in the notice entitled Conditions for Marketing New Drugs Evaluated in Drug Efficacy Study, published in the FEDERAL REGISTER July 14, 1970 (35 FR 11273), as follows:

a. For holders of "deemed approved" new drug applications (i.e., an application which became effective on the basis of safety prior to October 10, 1962), the submission of a supplement for revised labeling and a supplement for updating information, including full manufacturing information with respect to items 7 and 8 of Form FD-356H (§ 130.4(c)), as described in paragraph (a) (1) (i) and (ii) of the notice of July 14, 1970.

b. For any person who does not hold an approved or effective new drug application, the submission of an abbreviated new drug application as described in paragraph (a) (3) (i) of that notice, except that full manufacturing information with respect to items 7 and 8 of Form FD-356H (§ 130.4(c)) is required.

c. For any distributor of the drug, the use of labeling in accord with this announcement for any such drug shipped within the jurisdiction of the Act as described in paragraph (b) of that notice.

Each of the above-named holders of the new drug applications for these drugs has been mailed a copy of the Academy's report. Communications forwarded in response to this announcement should be identified with the reference number DESI 11673, directed to the attention of the following appropriate office, and addressed to the Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20852:

Supplements (identify with NDA number):
Office of Scientific Evaluation (BD-100),
Bureau of Drugs.

Original abbreviated new drug applications (identify as such): Drug Efficacy Study Implementation Project Office (BD-60),
Bureau of Drugs.

Requests for the Academy's report: Drug Efficacy Study Implementation Information Control (BD-66), Bureau of Drugs.

All other communications regarding this announcement: Drug Efficacy Study Implementation Project Office (BD-60),
Bureau of Drugs.

All identical, related, or similar products, not the subject of an approved new drug application, are covered by the new drug applications reviewed and are subject to this notice. See 21 CFR 130.40 (37 FR 23185, October 31, 1972). Any person who wishes to determine whether a specific product is covered by this notice should write to the Food and Drug Ad-

ministration, Bureau of Drugs, Office of Compliance (BD-300), 5600 Fishers Lane, Rockville, MD 20852.

This notice is issued pursuant to the Federal Food, Drug, and Cosmetic Act (secs. 502, 505, 52 Stat. 1050-53, as amended; 21 U.S.C. 352, 355) and the Administrative Procedure Act (5 U.S.C. 554), and under the authority delegated to the Commissioner of Food and Drugs (21 CFR 2.120).

Dated: February 7, 1973.

WILLIAM F. RANDOLPH,
Acting Associate Commissioner
for Compliance.

[FR Doc. 73-2718 Filed 2-9-73; 8:45 am]

[DESI 12101]

COMBINATION DRUG CONTAINING SYROSIINGOPINE AND HYDROCHLOROTHIAZIDE

Drugs for Human Use; Drug Efficacy Study Implementation

The Food and Drug Administration has evaluated reports received from the National Academy of Sciences-National Research Council, Drug Efficacy Study Group on the following drug:

Singoserp-Esldrix Tablets (2 strengths) containing syrosingopine and hydrochlorothiazide; Ciba Pharmaceutical Company, Division of Ciba-Geigy Corp., 556 Morris Avenue, Summit, NJ 07901 (NDA 12-101).

Such drugs are regarded as new drugs (21 U.S.C. 321(p)). The effectiveness classification is described below.

A. *Effectiveness classification.* The Food and Drug Administration has considered the Academy's reports, as well as other available evidence, and concludes that the drug is less than effective (possibly effective) for its labeled indications.

B. *Submission of data.* Any data submitted in response to this notice to support indications for which the drug is classified as less than effective must be previously unsubmitted and include data from adequate and well-controlled clinical investigations (identified for ready review) as described in § 130.12 (a) (5) of the regulations published in the FEDERAL REGISTER of May 8, 1970 (35 FR 7250). Carefully conducted and documented clinical studies obtained under uncontrolled or partially controlled situations are not acceptable as a sole basis for approval of claims of effectiveness, but such studies may be considered on their merits for corroborative support of efficacy and evidence of safety.

A copy of the Academy's report has been furnished to the firm referred to above. Communications forwarded in response to this announcement should be identified with the reference number DESI 12101, directed to the attention of the appropriate office listed below, and addressed to the Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20852.

Supplements (identify with NDA number):
Office of Scientific Evaluation (BD-100),
Bureau of Drugs.